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Introduction. Depression in adolescents and young people is associated with reduced social, occupational, and interpersonal
functioning, increases in suicide and self-harm behaviours, and problematic substance use. Age-appropriate, evidence-based
treatments are required to provide optimal care. Methods. “Evidence mapping” methodology was used to quantify the nature
and distribution of the extant high-quality research into the prevention and treatment of depression in young people across
psychological, medical, and other treatment domains. Results. Prevention research is dominated by cognitive-behavioral- (CBT-)
based interventions. Treatment studies predominantly consist of CBT and SSRI medication trials, with few trials of other
psychological interventions or complementary/alternative treatments. Quality studies on relapse prevention and treatment for
persistent depression are distinctly lacking. Conclusions. This map demonstrates opportunities for future research to address
the numerous evidence gaps for interventions to prevent or treat depression in young people, which are of interest to clinical
researchers, policy makers, and funding bodies.
1. Introduction
Depression among adolescents and young people is a press-
ing public health issue. A meta-analysis of prevalence rates
shows 2.8% of children (<13 years) and 5.7% of adolescents
(13–18 years) experience depression over a 12-month period
[1]. Depression has serious adverse effects on social, aca-
demic, and family functioning [2, 3]. Early onset depression
is also associated with higher rates of completed suicide and
suicide attempts compared to individuals with no psychiatric
illness [4, 5].
High prevalence and the associated disability of depres-
sive disorders make effective, evidence-based prevention and
early interventions a priority. While the status of depressive
disorders as a public health priority due to the associated
burden of disease [6] has ensured a large amount of effort
has gone into prevention research, an equally important, but
neglected focus has been on early intervention for those with
emerging or first episode depression.
The age of onset for most disorders, including depressive
and anxiety disorders, falls in a narrow time band, pre-
dominantly encompassing youth from the early teens to the
mid 20’s [7]. Early detection and intervention is critical to
preventing a relapsing or chronic course, which is associated
with the development of other psychiatric and alcohol and
substance use disorders [8, 9], impairments in occupational
and social functioning [3, 10–13], and the risk of suicide
[5, 14–16]. Harrington and Clark [17] demonstrated that
if all cases of depression in those aged 13 were treated
successfully then the risk of depressive disorder at age 16
years would be reduced by approximately 10%.
The idea of intervening early to assertively and effectively
treat depression and prevent the development of a relapsing
or chronic course is consistent with the clinical stagingmodel
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for psychiatry [18] that proposes that those in the early
stages of an illness respond better to treatment and thus
require more benign interventions whereas those with a
more developed disease process will require more complex
and perhaps invasive interventions [18]. Clinical staging is a
more refined form of diagnosis, placing emphasis on where a
person lies along the continuum of the course of illness [18–
22]. While yet to be fully realized, it provides a framework
for early intervention guiding the use of appropriate stage-
specific evidence based treatments, including preventatively
orientated treatments [18, 21, 22]. In the case of major
depression, research demonstrates that intervening during
these earlier stages is clinically warranted given the consider-
able impairment associated with “subthreshold” depression,
which is equally, if not more, prevalent than the diagnosable
disorder [11, 23].
This framework for early intervention relies on the
effective implementation of evidence-based practice. How-
ever, evidence-based interventions are far from universally
delivered, with research indicating, for example, that antide-
pressant medications with minimal empirical support are
prescribed to young people in high numbers [24, 25]. Having
access to, and being familiar with, the best available evidence
is a critical step in improving the uptake of evidence-based
practice.
One approach to summarising the large volume of
existing evidence is to undertake literature reviews. This
process has resulted in an array of different terminologies
and methodologies to describe approaches that share similar
characteristics, namely, collecting, evaluating, and presenting
the available research evidence [26]. Systematic reviews are
the most methodologically sound, as they use explicit meth-
ods of searching, appraising, and analyzing data to address
a focused clinical question [27]. Although methodologically
rigorous and providing useful summaries of the existing
published and unpublished data, they do not allow readers
a meaningful overview of all treatments across a population
with similar presentations, which has potential relevance to a
new and emerging field such as youth mental health.
Evidence mapping is a process of reviewing the literature
in a manner that enables the breadth of the research activity
in a particular field to be explored. While systematic reviews
can address specific clinical questions (e.g., is treatment
X effective for condition Y?), evidence mapping allows a
concise summary of the extent and distribution of evidence
in a broad field of interest (e.g., what interventions are
available for condition Y?). Evidence maps are based on an
explicit research question relating to the field of enquiry,
which may vary in depth, but should be informed by end
users. The research question then drives the search for,
and collection of, appropriate studies utilising explicit and
reproduciblemethods at each stage [26, 28, 29]. This includes
clear definition of components of the research question,
development of a thorough and reproducible search strategy,
development of explicit inclusion and exclusion criteria, and
transparent decisions about the level of information to be
obtained from each study. The end-user may be researchers
or research funding bodies who can identify gaps in the
evidence, which in turn will create opportunities for new
research and policy makers, who will use the evidence map
to inform policy decisions, or clinicians who can access
information about interventions.
This paper presents the results of an evidence map we
conducted on depression in young people. The extent, range,
and nature of high-quality clinical research interventions
for depression in young people is summarised. This process
of taking stock of the evidence is an essential first step in
obtaining an overview of the breadth of research activities
before further exploring the effectiveness of interventions.
2. Materials andMethods
The depression evidence map was produced as a part of a
larger evidence mapping project undertaken by the Centre
of Excellence in Youth Mental Health (part of headspace;
the Australian National Youth Mental Health Foundation;
http://www.headspace.org.au/). The centre is responsible for
generating and disseminating evidence regarding interven-
tions for adult-type mental health disorders that emerge dur-
ing adolescence and young adulthood. A detailed description
of the methodology for conducting these evidence maps
has been published elsewhere [28]; however, the methods
specific to the depression map are provided below.
Step 1. Create a Map Based on Broad Clinical Questions
Relating to the Field of Enquiry. After consulting with expert
research mental health clinicians (psychiatrists and psychol-
ogists) in depression prevention and intervention at Orygen
Youth Health Research Centre and headspace, the questions
and scope of the evidence map were defined. This process
revealed two areas of focus for the map, namely;
(I) What good-quality evidence exists regarding preven-
tion of and interventions for emerging or established
depressive disorders among young people?
(II) What areas are, and are not, well researched?
Step 2. Define Key Variables, Specifying Characteristics to
Be Mapped and Develop Inclusion and Exclusion Criteria.
Based on these key questions, the characteristics of studies
to be included in the map were defined, encompassing the
population, types of intervention, and phases of depressive
illness [28]. Intervention studies that had as their sample
adolescents and young adults aged 12–25 years old with
a depressive disorder, classified by the DSM-IV or ICD-
10 as the primary diagnosis, were included regardless of
the methods of assessment of depressive disorder. Studies
where participants were recruited on the basis of elevated
risk factors or subthreshold/subsyndromal presentations of
depression were also included and again the methods of
assessment varied across trials and were included regardless.
In the context of appropriately mapping the prevention and
early intervention research, prevention trials were including
if participants were aged 6 years and older. Trials with both
adult and adolescent participants were included if the mean
age of participants of any intervention group was at 25 years
of age or under. We excluded studies where participants were
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recruited on the basis of physiological or medical conditions
(e.g., depression in the context of experiencing cancer or
dementia). Interventions were defined as “anything delivered
for the purpose of relieving symptomatology or improving
functioning of the target disorder” [28].
Prevention trials were categorized into universal, selec-
tive, and indicated prevention. Universal interventions are
those delivered to a designated population regardless of their
risk; selected prevention interventions are those designed
to be delivered to members of the population with a risk
factor for a given disorder; indicated interventions are
those delivered to populations with signs or symptoms of
that disorder [30]. We combined selective and indicated
prevention trials into one category in the evidence map that
indicated populations “at risk.” The inclusion criteria for
relapse prevention studies required that the study specify that
the intervention was designed to prevent relapse or maintain
improvements in patients who had previously responded to
treatment. Subsequently, studies assessing an acute phase
intervention with a long-term phase were categorized as a
treatment study. In the depression literature, the definition
of treatment resistance (or more appropriately, persistent
depression) is an area of debate and an array of systems exist
to categorize different levels of nonresponse to treatment
[31]. As such, it was decided to include treatment-resistant
studies where the authors labeled them as such. We have
labeled these studies “persistent depression interventions”
as “treatment resistance” is arguably a pejorative term that
implies fault on the client’s behalf for being “resistant” to
treatment.
We sought to present “good-quality evidence,” and as
such we only utilized evidence from RCTs, pseudoran-
domised controlled trials, clinical controlled trials, system-
atic reviews, and meta-analyses, since these are commonly
considered the most robust study designs for examining
the effectiveness of interventions [32]. Definitions of review
types are not consistent and many different terms are used,
at times interchangeably [26], therefore we included those
reviews where a systematic search strategy was used. Included
studies were published in English from 1980 to May 2009.
Step 3. Searching the Literature. Search strategies for MED-
LINE, PSYCHINFO, EMBASE, and The Cochrane Central
Register of Controlled Trials (CENTRAL) were devised
using subject headings such as “depression,” “randomized
controlled trial,” and “review” appropriate for each database.
Additional free text words identified by experts were also
included. The search was broad and inclusive as the depres-
sion literature lacks clear early intervention terms such
as “ultra high risk” and “first episode” used in the early
psychosis field [33].
A filter to identify relevant publication types based on
the search strategy devised by Glanville et al. was also
incorporated [34]. The overall structure of searches targeted
and combined depression terms, study methodologies, stage
of illness terms, and were limited by year and English
language (a full search strategy is available upon request to
the corresponding author). Search strategies were revised
after a random sample of 100 citations retrieved for the
search was examined, as well as cross-checking the retrieval
for 20 articles known to meet the inclusion criteria.
Step 4. Screening and Positioning the Relevant Evidence within
the Map (e.g., Charting). The titles and abstracts of all po-
tentially relevant papers identified by the searches of all
databases were collated. All authors independently screened
100 references randomly selected from the search results
as a pilot trial to examine the consistency of applying the
inclusion and exclusion criteria. A satisfactory interrater re-
liability in excess of 0.90 was achieved for the pilot screening.
All authors were involved in the screening of retrieved cita-
tions. Where a title or abstract reported a trial that appeared
to be eligible for inclusion, the full article was obtained.
All references retained after the initial screening were then
assessed against the inclusion and exclusion criteria (PC)
based on their full texts. Trials with no information on
the age range or mean age of patients were excluded.
Reviews summarising evidence of treatments for both adults
and adolescents were included if there was specific content
devoted to the adolescent and young adult population.
References that met the inclusion criteria were then
coded according to the type of intervention, stage of depres-
sive illness, and study types. Intervention types were gener-
ally classified into psychological, biological, integrated, com-
plementary/alternative interventions and service/delivery
improvement. The stage of illness was coded as universal pre-
vention, selected/indicated prevention, disorder established,
and relapse prevention. Publication types were coded as
RCT/CCT (referred to as “trials” throughout results) and
systematic review (referred to as “reviews” throughout
results). Studies that evaluated the effectiveness of more than
one type of intervention were coded for each intervention,
thus the addition of the total number of studies from each
coded section is greater than the total number of included
studies.
The primary reference for each study was established
with secondary publications indicated as such. This process
prevented counting one study multiple times and misrep-
resenting the number of studies in a particular area. For
example, the Treatment of Adolescents with Depression
Study [35] has produced dozens of publications; however, it
is a single trial with 439 participants.
The current study goes beyond the scope of the overall
evidence mapping in that where a systematic review was
available and included in themap, a short qualitative descrip-
tion of the main conclusions has been provided.
3. Results
3.1. Included Trials. Our search strategies identified 32,733
references, of which 4,372 potentially relevant references
were retained based on the title and abstract. Full texts of
these references were retrieved. Based on the information
provided by the full text of the retrieved publications, 204
publications were included in the final map. These represent
a total of 162 trials, as well as 41 systematic reviews andmeta-
analyses (see Figure 1). A list of citations for all RCTs and
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Total references retrieved
32.733
Excluded based on title and
abstract
28.361
Full text retrieved
4.372
Excluded based on full text
4.165
Number of included studies
204
Figure 1: Distribution of included universal preventive studies.
systematic reviews included in the map are available on
request or the included studies can be found on our search-
able database (http://www.headspace.org.au/what-works/ev-
idence-maps).
3.2. Universal Prevention Studies. A total of 23 universal pre-
vention studies were identified, consisting of 18 RCTs and 5
systematic reviews (Figure 2). Of the 18 trials, 15 focused on
cognitive behavioural therapy (CBT), many originating from
the University of Pennsylvania (e.g., the Penn Prevention
Programme and the Penn Resiliency Programme [36, 37]).
The remaining trials utilized interpersonal (n = 2), family
(n = 2), psychoeducation (n = 1), and leadership (n = 1)
programs.
There were no universal prevention trials utilising
complementary or alternative interventions. However, one
Cochrane systematic review was included that explored the
benefits of exercise as a preventative intervention.
Reviews of universal interventions are common and
provide useful summaries of existing trials. Themap includes
four general reviews of various types of universal interven-
tions, most commonly delivered in group format [38–41].
These reviews are generally cautious in their support of
universal prevention programs for children and adolescents
because such interventions were not consistently shown to
be effective in a recent review (e.g., [41]). It has been
suggested that this may be due to the low effect sizes
typically demonstrated in universal prevention studies [41].
The reviews highlight the need for more research given some
promising results (e.g., [42] in [41]) and in combination with
the potential benefits of universal prevention programs that
are less stigmatising than selected prevention interventions
and potentially cost-effective ways to reduce depression in
the community [41].
3.3. Selective and Indicated Prevention Studies. In total,
54 studies were identified, consisting of 43 trials and 11
systematic reviews (Figure 3). The majority of research again
focused on CBT-based interventions (n = 28). There were 2
studies of interpersonal psychotherapy (IPT), although only
one involved IPT as the primary intervention. There was
one study each of exercise, psychoeducation, play therapy,
and skills training, and 4 complementary and alternative
interventions (n = 4).
Seven reviews were included that assessed all types of
interventions for those at risk of depression. Generally,
targeted interventions, which were again mostly delivered
in a group format, were found to be effective in preventing
depression immediately after the delivery of interventions,
although robust long-term effects are still to be shown [43–
45]. CBT programs in particular have been consistently
found to be effective in preventing depression in at-risk
young people [41, 44, 45] with one review [41] highlighting
the effectiveness of a CBT based program called “Coping with
Depression,” even at long term followup [46, 47].
3.4. Interventions for Diagnosed Depression (Established Disor-
der). There were 129 studies of interventions for depressive
disorders, of which 81 involved biological interventions
(n = 56 trials; n = 25 systematic reviews), predominantly
antidepressant medications (n = 78). A total of 58 studies
involved psychological interventions (48 trials, 10 systematic
reviews) and four studies of complementary and alternative
interventions (3 trials, 1 systematic review; Figure 4).
Of the 78 studies investigating medications, the major-
ity involved selective serotonin reuptake inhibitors (SSRIs;
n = 45). There were fewer trials of tricyclic antidepres-
sants (TCAs; n = 23), serotonin-norepinephrine reuptake
inhibitors (SNRIs; n = 3), and only one trial of monoamine
oxidase inhibitors (MAOIs). Of the included systematic
reviews, 13 analysed SSRIs, three examined TCAs, and one
SNRIs. The earlier reviews assessing TCAs concluded that
TCAs were no more effective than placebo in improving
depression outcomes [48, 49]. A more recent systematic
review reported comparable results, adding that the dif-
ference between TCAs and placebo remains nonsignificant
with the addition of open-label trials into the meta-analysis
[50]. The reviews of SSRIs have highlighted fluoxetine as
the SSRI with the most favorable risk-benefit profile [51–
54] but there has been vigorous debate about the findings
[55, 56]. For example, doubts have been raised about the
clinical meaningfulness of the size of the effect in the context
of trial participants who are not representative of those
typically seen in clinical practice, as well as concerns about
methodological aspects of the trials such as high drop-out
rates and high rates of placebo response [56]. Ameta-analysis
including the SNRI venlafaxine concluded that results were
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Stage of
illness
Intervention
type
Intervention Trials Reviews
Universal
prevention
Psychological
Cognitive behavioural
therapy
Interpersonal therapy
Family therapy
Psychoeducation
Psychological
Psychological
15 1
2 0
2 0
1 0
0 4
1 1
—general
—other
Figure 2: Flowchart for included studies.
Stage of
illness
Intervention
type
Intervention Trials Reviews
At risk Psychological Cognitive behavioural therapy
Interpersonal therapy
Family therapy
Supportive therapy
Psychodynamic/psychoanalysis
Problem-solving therapy
Play therapy
Motivational interviewing
Psychoeducation
Skills training
Psychological
Psychological
CAM CAM
28 3
2 0
0 0
0 0
0 0
0 0
1 0
1 0
1 0
1 0
5 1
0 7
4 1
—general
—other
Figure 3: Distribution of included indicated and selective preventive studies.
inconclusive as trials had not adequately assessed the safety
and efficacy of this drug [57].
Of the 58 studies of psychological interventions, CBT
was by far the most well studied (33 trials and 5 systematic
reviews). There were fewer intervention studies of other
psychological therapies in young people, with 7 trials for IPT
and 6 for family therapy. There were no published systematic
reviews for these treatment modalities alone. One trial exam-
ined psychodynamic psychotherapy. The most recent review
included in the map [58] was of psychotherapies and 25 of 35
comparisons investigated the effectiveness of CBT, including
the more well known of the named CBT programs that
is delivered in group format called the “Adolescent Coping
with Depression Course” [59–61]. Comparison groups were
mostly waiting list control or no treatment groups. Most
of the participants were female adolescents with mild to
moderate depression recruited from schools. Psychotherapy
overall was superior to control conditions after intervention
with an NNT of 4.3, as was CBT, behavioural therapy, and
interpersonal therapy; however, this evidence of the effective-
ness did not remain at longer-term followup [58].
There were 10 trials that compared a psychological ther-
apy with an antidepressant medication and/or a combination
of the two, including the very well-known Treatment for
Adolescent Depression (TADS) trial. The therapy arms of the
10 trials all had a CBT underpinning, and the medications
were all SSRIs, except one that assessed venlafaxine. There
were no systematic reviews identified comparing psycho-
logical therapies with antidepressant medications and/or a
combination of a psychological therapy plus a medication.
3.5. Relapse Prevention and Interventions for Persistent Depres-
sion. Research into relapse prevention among young people
with depressive disorders is limited. Four trials have assessed
SSRIs in relapse prevention and one CBT. No systematic
reviews were identified. There is a similar paucity of studies
investigating interventions for young people with persistent
depressive disorders, with only two trials identified, one of
which investigated the efficacy of antidepressant medication
in the context of a hospital admission [62] and one, the
TORDIA study, which assessed the efficacy of combined
antidepressants and CBT [63].
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Stage of
illness
Intervention
type
Intervention Trials Reviews
Psychological Cognitive behavioural therapy
Interpersonal therapy
Family therapy
Supportive therapy
Psychodynamic/psychoanalysis
Problem-solving therapy
Play therapy
Psychoeducation
Psychological
Psychological
33 5
7 0
6 0
4 0
1 0
2 0
1 0
1 0
7 0
0 5
1 9
32 13
19 4
3 1
1 0
1 0
1 0
1 0
1 0
1 0
3 1
Disorder
established
Biological Antidepressants
SSRI
TCA
SNRI
MAOI
NRI
TMS
Anticonvulsants
Lithium
Neutraceuticals
CAM CAM
—general
—other
—general
Figure 4: Distribution of included studies to treat a diagnosed depressive disorder.
4. Discussion
Mapping methodology allows for a clear presentation of the
nature and extent of high-quality interventions in a broad
research field. The evidence map for depression in young
people reveals the considerable research into CBT for the
prevention of depression, and both CBT and SSRIs for those
with a diagnosed depressive disorder, while simultaneously
exposing the numerous opportunities for innovative research
in this area, most notably for other evidence-based psy-
chological treatments for established disorders (e.g., IPT,
problem-solving therapy, and family therapy) and research
more broadly into relapse prevention strategies in this
population.
4.1. Opportunities for Future Prevention Research. There is
a considerable literature for prevention research, which is
currently dominated by studies of psychological interven-
tions, and in particular those based on CBT. Systematic
reviews, while showing the potential to effectively prevent
depression in young people, indicate highly variable results
from different individual trials. Future research should
investigate the most efficacious CBT programs or “active
ingredients” of these programs in order to further refine or
simplify the interventions.
Future research into the prevention of depression should
also consider both new therapeutic approaches and less
intensive approaches. Although CBT is a well-founded
therapeutic therapy, a narrow focus on this approach could
potentially delay significant advancement in the field of
preventive interventions. This is particularly the case given
that, in many countries, CBT can only be provided by a
clinical or registered psychologist. By virtue of the shortage
of psychologists in many communities, some new initiatives
have focused on delivering CBT by nonpsychologists such
as the Improving Access to Psychological Therapies in the
United Kingdom [64]. Other alternatives are to assess the
efficacy of simpler interventions such as psychoeducation,
or problem solving therapy (PST), both of which have been
shown to be effective tools in helping to reduce depressive
symptoms in young people [65, 66] but currently lack the
breadth of high-quality research devoted to CBT. That low-
intensity interventions such as psychoeducation and PST
have the potential to be delivered by nonmental health
specialists, such as teachers or general medical practitioners,
will increase the scope for their uptake in the community,
which is crucial for prevention strategies [67]. More intensive
approaches such as IPT, family therapy, or acceptance and
commitment therapy may also be beneficial as potential
as preventative interventions, particularly for those young
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people identified as being at risk of developing depression,
although this is yet to be adequately explored in clinical trials.
Finally, given many young peoples’ enthusiasm for mod-
ern technology, there is potential for more quality research
into the efficacy of intervention delivered using electronic
technologies, including SMS, email, and Internet-based pro-
grams [68, 69]. Delivery of interventions such as psychoedu-
cation, PST, or CBT via electronic means to both populations
at risk of depressive disorders, as well as those targeted by
universal prevention programs, appears warranted given the
prevalence of depressive symptoms.
4.2. Opportunities for Research for Those with Established
Depressive Illnesses. Intervention studies among young peo-
ple with diagnosed depression have been dominated by trials
of antidepressant medications and CBT trials. Trials and
reviews of SSRIs are the most commonly studies biological
intervention and generally conclude that there is evidence
for the effectiveness of fluoxetine compared with placebo,
with inconsistent evidence for other medications in this class
[51–54, 70]. However the clinical significance of the results
from these trials have been described as far from compelling,
with criticisms directed at methodological aspects of the
trials including high drop-out rates and high placebo-
response rates, concerns about the measurement tools used
with questions raised about whether the difference in effect
between SSRIs and placebo reflects a difference that is of
clinical importance to patients, and concerns about the
representativeness of the included participants [54]. A newer
class of antidepressants, the SNRIs, have only been subject to
three RCTs. While there is considerable research comparing
antidepressants to placebo in young people, there is a paucity
of research comparing antidepressants head to head, which is
an area for greater enquiry, particularly given the relevance to
clinicians when deciding which medication to choose.
In terms of psychological interventions, there is again
scope to extend the high-quality research beyond CBT
to examine other interventions (both simple and more
complex), particularly for early or first episodes of disorder,
or for less severe depressive disorders in young people. These
might include, for example, supportive case management
without formal intervention, which was shown in the
ADAPT trial to be beneficial for 21% of participants, who
were excluded from the intervention phase of the trial
because they responded to this brief initial intervention [71].
The National Institute for Health and Clinical Excellence
(NICE) guidelines for the identification and treatment of
depression in young people also recommends a range of
guided self-help approaches that can be useful at early
stages of illness [72]. These include exercise, sleep hygiene,
anxiety management, and improved nutrition. There are
also biological interventions (neutraceuticals) such as fish
oil, light therapy, saffron, and folate that have preliminary
evidence of effectiveness in adult populations [73], which
could be trialed in young people. These interventions
are consistent with guideline recommendations of using
low-intensity interventions first, before advancing to more
complex interventions delivered by mental health specialists.
Furthermore, before further trials of psychotherapeutic
interventions are conducted, systematic reviews of interven-
tion studies for IPT and family therapy should be conducted
and used to direct further research into these promising
approaches. Finally, while short-term psychodynamic psy-
chotherapy and the newer “third wave” CBT therapies like
acceptance and commitment therapy (ACT) have has been
well studied in adults with depression [74, 75], these are yet
to be tested in young people using high-quality controlled
trials.
4.3. Opportunities for Research in Relapse Prevention and
Persistent Depression Strategies. Early onset depression is
associated with higher rates of relapse than adult onset [76].
Of adolescents who experience an episode of depression
one-third to one-half will go on to experience subsequent
episodes in within four to seven years [77, 78] and hence
the need to establish effective relapse prevention approaches
is critical. The lack of relapse prevention trails in young
people with depression is one of the most striking findings
of the evidence map, and one of the most disappointing.
In order to avert longer-term disability associated with
multiple episodes of illness, or persistent depression, research
in this area is urgently required. Such studies should be
distinct from standard maintenance phases in RCTs and
involve rerandomization of treatment responders (which is
acknowledged to require significant sample sizes to overcome
power issues). While cognitive, and mindfulness-based,
cognitive therapy shows promise in adults (e.g., [79, 80])
potential relapse prevention trials could include not just CBT,
but other psychosocial interventions such as family therapy,
group programs, and vocational interventions, which have
been shown to be effective in young people with first episode
psychosis [81].
Finally, while research focusing on interventions for
“treatment resistant” depression (e.g., failure to respond to
more than 3 treatments) in young people is not surprisingly
rare given their age, there are research opportunities for
further evaluating repetitive Transcranial magnetic stimu-
lation (rTMS) in young people with severe depression that
has not previously responded to adequate trials of CBT
and/or antidepressant medications. rTMS is said to change
brain activity through energy delivered via the magnetic filed
created around the brain area it is applied to. It has shown
promise as an intervention for treatment resistant depression
in adults with a favorable side effect profile [82–84].
4.4. Limitations. A limitation of the current study is that
there was no evaluation of the effectiveness of the inter-
ventions within the trials, restricting us from drawing any
conclusions on intervention efficacy. The primary limitation
of the current study is the focus on “gold standard” research,
which neglects important information available from studies
using designs other than the randomized controlled trial
and systematic review. Due to resource constraints, trials
were also limited to those published after 1980 in English,
and quality appraisal of the included studies could not
be undertaken. Nonetheless, this evidence map has sys-
tematically demonstrated what high-quality evidence does
8 Depression Research and Treatment
exist for prevention and treatment interventions for young
people with depression and has exposed gaps in the research
evidence in order to inform researchers, funding bodies, and
policy makers as to the opportunities for future research.
5. Conclusions
Depressive disorders are currently the leading cause of years
of life lived with disability in developed countries and are
projected to be second only to cardiovascular disease as the
cause of all disability adjusted life years by 2020 [6]. As the
onset of depression frequently occurs during adolescence and
young adulthood, there is a pressing need to develop effective
interventions both to prevent depression in those at risk, and
ameliorate symptoms and restore psychosocial functioning
in those that experience a depressive episode. Significant
gains in this area may be achieved by focusing more on
early intervention in this field, particularly the opportunities
for responding more comprehensively to “first episode
depression” and relapse prevention in younger clients, which
has been demonstrated to be highly effective in the clinical
management of early psychosis [85–87]. Currently the bulk
of expenditure is geared towards acute treatment of diag-
nosed conditions [88]; however, early intervention would in
all likelihood convey significant savings both economically
and also in terms of the personal costs associated with a
potentially chronic depressive disorder.
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